Analysts Set Expectations for CGTX FY2026 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Brookline Capital Markets upped their FY2026 earnings estimates for Cognition Therapeutics in a research report issued to clients and investors on Thursday, November 5th. Brookline Capital Markets analyst F. Ahmed now expects that the company will post earnings of ($0.20) per share for the year, up from their prior estimate of ($0.42). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for Cognition Therapeutics’ Q4 2026 earnings at ($0.06) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03.

A number of other analysts also recently weighed in on CGTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a research report on Monday, October 5th. Finally, Wall Street Zen cut Cognition Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $3.33.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock opened at $0.69 on Tuesday. The stock’s fifty day moving average price is $0.87 and its two-hundred day moving average price is $1.05. Cognition Therapeutics has a one year low of $0.55 and a one year high of $1.82.

Institutional Trading of Cognition Therapeutics

Several large investors have recently made changes to their positions in CGTX. Lido Advisors LLC bought a new stake in shares of Cognition Therapeutics during the third quarter worth $44,000. StoneX Group Inc. bought a new position in shares of Cognition Therapeutics in the 3rd quarter valued at $30,000. Sigma Planning Corp lifted its stake in shares of Cognition Therapeutics by 7.3% in the 2nd quarter. Sigma Planning Corp now owns 362,265 shares of the company’s stock valued at $417,000 after acquiring an additional 24,500 shares during the last quarter. Corient Private Wealth LP bought a new position in shares of Cognition Therapeutics in the 2nd quarter valued at $93,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in shares of Cognition Therapeutics during the 2nd quarter valued at $369,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.